Associate Professor Daniel Thomas
Associate Professor Haematology
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD, but is currently at capacity - email supervisor to discuss availability.
With unique training experience at the Stanford University School of Medicine, Daniel Thomas is a clinical haematologist and cancer scientist whose goals are to develop new drugs and better outcomes for the treatment of rare and hard-to-treat cancers and lead a creative and innovative cancer research laboratory. The core values in Dan's lab are Creativity (not being afraid to try something new), Compassion (identifying with cancer patients and their carers to learn what really matters) and Generosity (sharing new technologies to other researchers to move the field forward).
- My Research
- Career
- Publications
- Grants and Funding
- Teaching
- Supervision
- Professional Activities
- Contact
Dan is currently Program Director for Blood Cancers at SAHMRI and leads the Myeloid Metabolism Lab led by Dan Thomas is located on Level 5 of the main SAHMRI building (Precision Medicine, Cancer Theme, adjacent to the Royal Adelaide Hospital and 10 minutes from Adelaide International airport). The lab is focused on interplay between cancer, metabolism and epigenetics. Dr Daniel Thomas is a clinical haematologist and pathologist whose goals in research are to develop new drugs for the treatment of cancer using expanded human myeloid progenitors, mass spectrometry and computational tools. He has had post-doctoral training experience at the Stanford School of Medicine, Institute of Stem Cell & Regenerative Medicine, led by Irving Weissman and direct mentoring from Professor Ravindra Majeti (discovery of CD47 and pre-leukaemic stem cells). Key equipment accessible from Dan's laboratory including Seahorse Xfe96, Vistaflux software with Agilent 6546 Q-ToF metabolomics solution, BRAVO liquid handing robot, human metabolome shRNA bar-coded library, 10X single cell transcriptomics, ARIA FACS sorter & serial blood cancer patient samples. If you are passionate about thinking outside the square to improve the treatment of cancer, please contact Dr Thomas about potential student internships.
The Thomas Lab has a strong track record in finding new druggable targets in cancer and predicting mutations that respond to specific targeted therapies as well as repurposing old drugs for new uses in cancer. Some of the discoveries that Dr Thomas has contributed to are already in the clinic or are under clinical investigation, including a humanized monoclonal antibody for the treatment of myelofibrosis (EMBO Reports, 2022), JAK2 mutations (Blood Cancer Discovery, 2023) and precision dietetics for IDH1 mutated cancers (Cancer Discovery, 2022). Dan leads an international biannual conference, New Directions in Leukaemia Research (2022 in Brisbane, 2024 in Adelaide and 2026) that brings scientists and doctors together to discover new treatments for blood cancers and leukaemia. Dan's lab is leading the first precision medicine trial nationwide for a rare and poor prognosis blood cancer called CMML, chronic myelomonocytic leukaemia using monoclonal antibodies and high dose Vitamin Chttps://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380941&isReview=true. Recently, members of his team led by Professor Hiwase described a new form autoimmune disease linked to IDH1 mutations in cancer (Blood, 2024).
Other research contributions include (i) mutation-specific drug targets for acute myeloid leukaemia (EZH2 for AML with WT1 mutation, Blood 2015; Bcl2 as a target for cancer with IDH1 mutation, Nature Med 2016; ROS activation for AML with NPM1 mutation, Leukemia 2014; ACC1 for AML with IDH1 mutation, Nature Com, 2017), (ii) prediction of 145,891 synthetic partners for 3,120 recurrent mutations for 12 cancer types (Leukemia 2019, first author and co-inventor Nature Com, 2017, (iii) pre-clinical development of a biological therapy (humanized monoclonal antibody directed against CD123 Cell Stem Cell, 2009, Leukemia 2014) (iv) pre-clinical development of a biological therapy for myelofibrosis (Science Adv 2018), (v) repurposing medicines for treatment of leukaemia (JCI 2020, Scientific Reports 2019, J of Hepatology 2020) and (iv) translational experience in the Stanford Alliance for Innovative Medicines program.
Dr Thomas has been awarded a number of prizes for his work including the CSL Centenary Fellowship ($1.25M), K99-R00 Pathway to Independence award by the National Cancer Institute, NHMRC PhD award, Albert Bakie Medal, Douglas Hardy Prize, Nimmo Prize and CJ Martin Biomedical Fellowship, The Hospital Research Foundation 2020, 2 Ideas grants NHMRC 2020, MRFF funding 2020 for a precision medicine trial "Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort ". Dr Thomas received competitive grant funding for the 2020, 2022 and 2023 Translational Research Program/ Synergistic Team Awards from United States Leukemia & Lymphoma Society co-funded by The Leukaemia Foundation and Snowdome.
The over-arching goal of Dan’s research is to find novel mutation-specific drug targets for somatic mutations, especially in poor prognosis and difficult to treat cancer types, using leukemia as a test bed. The lab has unique skills in developing humanized in vivo models for AML, isolation and testing of pre-leukemia stem cells and bioinformatic algorithms together with key academic and industry networks.
Links to more information about The Myeloid Metabolism Lab:-
https://www.leukaemia.org.au/stories/an-antibody-for-myelofibrosis-thats-a-true-discovery/
https://www.leukaemia.org.au/stories/a-new-era-of-medicine/
https://www.adelaide.edu.au/newsroom/news/list/2020/06/29/162-million-for-rare-cancer-research
https://www.cslfellowships.com.au/fellows-archive/associate-professor-daniel-thomas-bio
-
Appointments
Date Position Institution name 2022 - ongoing Haematology Consultant Royal Adelaide Hospital 2019 - ongoing Titleholder Stanford University School of Medicine 2019 - ongoing Myeloid Metabolism Lab Leader and Program Leader Blood Cancer, Precision Medicine Theme South Australian Health and Medical Research Institute 2019 - ongoing CSL Fellow and Associate Professor The University of Adelaide 2017 - 2019 Instructor/Junior Faculty Stanford University School of Medicine 2010 - 2012 Staff Specialist Royal Adelaide Hospital 2000 - 2000 Resident Royal Adelaide Hospital -
Awards and Achievements
Date Type Title Institution Name Country Amount 2018 Award Stanford Alliance of Innovative Medicines Award Stanford University United States - 2015 Award Honorary Award for Outstanding Presentation, Stanford Hematology-Oncology Retreat Stanford University School of Medicine United States - 2015 Award Outstanding External Grant Reviewer for 2014 National Health and Medical Research Council of Australia Australia - 2014 Award Best Publication for Previous Year Centre for Cancer Biology Australia - 2014 Award Leukemia Foundation New Investigator Award Leukemia Foundation Australia - 2014 Award Outstanding Young Investigator Award, New Directions in Leukemia Research Conference New Directions in Leukemia Research Australia - 2012 Distinction Dean’s Commendation for Doctoral Thesis Excellence for PhD The University of Adelaide Australia - 2012 Fellowship CJ Martin Overseas Biomedical Fellowship NHMRC Australia $375,828 2011 Fellowship HOTT Haematology/Oncology Targetted Therapy Fellowship Haematology Society of Australia & New Zealand/COSA/Roche/COGA Australia - 2010 Award Nimmo Prize, Best Full-Time Research Royal Adelaide Hospital Australia - 2010 Award Outstanding Research Presentation Prize, New Directions in Leukaemia Conference New Directions in Leukaemia Research (NDLR) Australia - 2010 Fellowship HSANZ Haematology Targeted Therapy Fellowship The Haematology Society of Australia and New Zealand Australia - 2008 Award National Adult Medicine Research Award Royal Australasian College of Physicians Australia - 2007 Award Albert Baikie Memorial Medal Haematology Society of Australia & New Zealand Australia - 2007 Award John Chalmers Prize for Best Medical Research Presentation Royal Australasian College of Physicians Australia - 2007 Scholarship The NHMRC Postgraduate Scholarship National Health & Medical Research Council Australia - 2004 Award Hugh Gilmore Prize for Best Presentation of Medical Research by a Physician in Training Royal Adelaide Hospital Australia - -
Education
Date Institution name Country Title 2012 University of Adelaide Australia PhD 2000 University of Adelaide Australia Bachelor of Medicine and Bachelor of Surgery 1998 University of Adelaide Australia Bachelor of Medical Science (Honours) -
Postgraduate Training
Date Title Institution Country 2012 - 2013 Postdoctoral Fellow Stanford University School of Medicine United States -
Certifications
Date Title Institution name Country 2007 Fellow (FRACP) Royal Australasian College of Physicians Australia 2007 Fellow (FRCPA) Royal College of Pathologists of Australasia Australia -
Research Interests
-
Journals
Year Citation 2023 Kan, W. L., Dhagat, U., Hercus, T. R., Kaufmann, K. B., Nero, T. L., Zeng, A. G. X., . . . Lopez, A. (2023). Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia. Cancer Discovery, 13(8), 1922-1947.
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. Blood Cancer Discovery, 4(5), 352-364.
Scopus12023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 1 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 2 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary Methods from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary Figure S1 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary Movie from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 2 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 1 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
2023 Sharplin, K., Proudman, W., Chhetri, R., Tran, E. N. H., Choong, J., Kutyna, M., . . . Hiwase, D. (2023). A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data. Cancers, 15(16), 1-14.
Scopus12023 Thomas, D., Wu, M., Nakauchi, Y., Zheng, M., Thompson-Peach, C. A., Lim, K., . . . Majeti, R. (2023). Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discovery, 13(2), 496-515.
Scopus13 WoS7 Europe PMC92023 Hiwase, D. K., Hahn, C. N., Tran, E. N. H., Chhetri, R., Baranwal, A., Al-Kali, A., . . . Shah, M. V. (2023). TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood, 141(9), 1087-1091.
Scopus9 WoS7 Europe PMC62023 Foßelteder, J., Pabst, G., Sconocchia, T., Schlacher, A., Auinger, L., Kashofer, K., . . . Reinisch, A. (2023). Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities. Leukemia, 37(4), 843-853.
Scopus4 Europe PMC22023 Shah, M. V., Tran, E. N. H., Shah, S., Chhetri, R., Baranwal, A., Ladon, D., . . . Hiwase, D. K. (2023). TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer Journal, 13(1), 51-1-51-9.
Scopus5 WoS2 Europe PMC42023 Thompson-Peach, C. A. L., Foßelteder, J., Reinisch, A., & Thomas, D. (2023). Thrombopoietin-independent Megakaryocyte Differentiation of Hematopoietic Progenitor Cells from Patients with Myeloproliferative Neoplasms. Bio-protocol, 13(2).
2022 Nakauchi, Y., Azizi, A., Thomas, D., Corces, M. R., Reinisch, A., Sharma, R., . . . Majeti, R. (2022). The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia. Blood Cancer Discovery, 3(4), 346-367.
Scopus15 WoS10 Europe PMC102022 Tvorogov, D., Thompson-Peach, C. A. L., Foßelteder, J., Dottore, M., Stomski, F., Onnesha, S. A., . . . Lopez, A. F. (2022). Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody. EMBO Reports, 23(4), e52904-1-e52904-12.
Scopus9 WoS8 Europe PMC102022 Lewis, A. C., Pope, V. S., Tea, M. N., Li, M., Nwosu, G. O., Nguyen, T. M., . . . Pitson, S. M. (2022). Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.. Blood, 139(26), 3737-3751.
Scopus19 WoS9 Europe PMC152022 Bassal, M. A., Samaraweera, S. E., Lim, K., Bernard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications, 13(1), 1-12.
Scopus8 WoS8 Europe PMC72022 Bassal, M. A., Samaraweera, S. E., Lim, K., Benard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.. Nat Commun, 13(1), 4131.
Scopus1 WoS12022 Downes, C. E., McClure, B. J., McDougal, D. P., Heatley, S. L., Bruning, J. B., Thomas, D., . . . White, D. L. (2022). JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies. Frontiers in Cell and Developmental Biology, 10, 1-34.
Scopus13 WoS8 Europe PMC62022 Kutyna, M. M., Kok, C. H., Lim, Y., Tran, E. N. H., Campbell, D., Paton, S., . . . Hiwase, D. K. (2022). A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure. Leukemia, 36(11), 2678-2689.
Scopus10 WoS4 Europe PMC82021 Ross, D. M., Babon, J. J., Tvorogov, D., & Thomas, D. (2021). Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications. Haematologica, 106(5), 1244-1253.
Scopus14 WoS9 Europe PMC82021 Singhal, D., Hahn, C. N., Feurstein, S., Wee, L. Y. A., Moma, L., Kutyna, M. M., . . . Hiwase, D. K. (2021). Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 35(11), 3245-3256.
Scopus34 WoS26 Europe PMC252021 Lim, K., Thompson-Peach, C., & Thomas, D. (2021). Neonatal heel prick mass spectrometry identifies metabolic predictors of AML latency. Leukemia Research, 109, 1-3.
Scopus1 WoS12021 Thomas, D. (2021). Machine learning finds new AML subtypes. Blood, 138(19), 1790-1792.
Scopus12021 Benard, B. A., Leak, L. B., Azizi, A., Thomas, D., Gentles, A. J., & Majeti, R. (2021). Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia. Nature Communications, 12(1), 1-13.
Scopus26 Europe PMC272021 Sharplin, K., Wee, L. Y. A., Singhal, D., Edwards, S., Danner, S., Lewis, I., . . . Hiwase, D. K. (2021). Outcomes and health care utilization of older patients with acute myeloid leukemia.. Journal of geriatric oncology, 12(2), 243-249.
Scopus5 WoS4 Europe PMC52020 Guan, Y., Chen, X., Wu, M., Zhu, W., Arslan, A., Takeda, S., . . . Peltz, G. (2020). The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy. Journal of Hepatology, 72(4), 16 pages.
Scopus30 Europe PMC222020 Dutta, R., Zhang, T. Y., Köhnke, T., Thomas, D., Linde, M., Gars, E., . . . Majeti, R. (2020). Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2. Journal of Clinical Investigation, 130(4), 1843-1849.
Scopus22 Europe PMC152019 Benard, B., Gentles, A. J., Köhnke, T., Majeti, R., & Thomas, D. (2019). Data mining for mutation-specific targets in acute myeloid leukemia. Leukemia, 33(4), 826-843.
Scopus15 Europe PMC102019 Benard, B., & Thomas, D. (2019). Predicting response to new drugs in AML from simulation modelling: Value of the BEAT AML project as a validation resource. Leukemia Research, 80, 43-44.
2019 Li, Y., Thomas, D., Deutzmann, A., Majeti, R., Felsher, D. W., & Dill, D. L. (2019). Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Scientific Reports, 9(1), 16775.
Scopus16 Europe PMC112018 Gars, E., Kaur, S., & Thomas, D. (2018). Endothelin receptor emerges as a potential target of Hoxa9-mediated leukemogenesis. Leukemia Research, 75, 69-70.
2018 Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., . . . Lopez, A. F. (2018). Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances, 4(11), 1-12.
Scopus37 WoS34 Europe PMC302017 Powell, J., Lewis, A., Zhu, W., Toubia, J., Pitman, M., Wallington-Beddoe, C., . . . Pitson, S. (2017). Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.. Blood, 129(6), 771-782.
Scopus67 WoS59 Europe PMC482017 Sinha, S., Thomas, D., Chan, S., Gao, Y., Brunen, D., Torabi, D., . . . Dill, D. L. (2017). Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications, 8(1), 1-13.
Scopus68 Europe PMC412017 Thomas, D., & Majeti, R. (2017). Optimizing next-generation AML therapy: Activity of mutant IDH2 inhibitor AG-221 in preclinical models. Cancer Discovery, 7(5), 459-461.
Scopus13 Europe PMC82017 Thomas, D., & Majeti, R. (2017). Biology and relevance of human acute myeloid leukemia stem cells. Blood, 129(12), 1577-1585.
Scopus315 Europe PMC2182016 Thomas, D., & Majeti, R. (2016). Burning Fat Fuels Leukemic Stem Cell Heterogeneity. Cell Stem Cell, 19(1), 1-2.
Scopus5 Europe PMC122016 Huang, M., Garcia, J. S., Thomas, D., Zhu, L., Truong Nguyen, L. X., Chan, S. M., . . . Mitchell, B. S. (2016). Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget, 7(46), 74917-74930.
Scopus8 Europe PMC52016 Reinisch, A., Thomas, D., Corces, M. R., Zhang, X., Gratzinger, D., Hong, W. J., . . . Majeti, R. (2016). A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nature Medicine, 22(7), 812-821.
Scopus160 Europe PMC1222016 Smith, A. M., Dun, M. D., Lee, E. M., Harrison, C., Kahl, R., Flanagan, H., . . . Verrills, N. M. (2016). Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 7(30), 47465-47478.
Scopus35 WoS35 Europe PMC202015 Mazumdar, C., Shen, Y., Xavy, S., Zhao, F., Reinisch, A., Li, R., . . . Majeti, R. (2015). Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell, 17(6), 675-688.
Scopus153 Europe PMC1322015 Raval, A., Behbehani, G. K., Nguyen, L. X. T., Thomas, D., Kusler, B., Garbuzov, A., . . . Mitchell, B. S. (2015). Reversibility of defective hematopoiesis caused by telomere shortening in telomerase knockout mice. PLoS ONE, 10(7), 1-20.
Scopus18 Europe PMC162015 Reinisch, A., Etchart, N., Thomas, D., Hofmann, N. A., Fruehwirth, M., Sinha, S., . . . Strunk, D. (2015). Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood, 125(2), 249-260.
Scopus175 Europe PMC1362015 Sinha, S., Thomas, D., Yu, L., Gentles, A. J., Jung, N., Corces-Zimmerman, M. R., . . . Majeti, R. (2015). Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood, 125(2), 316-326.
Scopus38 Europe PMC252015 Reinisch, A., Chan, S. M., Thomas, D., & Majeti, R. (2015). Biology and clinical relevance of acute myeloid leukemia stem cells. Seminars in Hematology, 52(3), 150-164.
Scopus52 Europe PMC422015 Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W. J., . . . Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine, 21(2), 178-184.
Scopus434 Europe PMC3292014 Busfield, S., Biondo, M., Wong, M., Ramshaw, H., Lee, E., Ghosh, S., . . . Nash, A. (2014). Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia, 28(11), 2213-2221.
Scopus116 WoS108 Europe PMC812013 Lonic, A., Powell, J., Kong, Y., Thomas, D., Holien, J., Truong, N., . . . Guthridge, M. (2013). Phosphorylation of serine 779 in fibroblast growth factor receptor 1 and 2 by protein Kinase C(epsilon) regulates Ras/mitogen-activated protein kinase signaling and neuronal differentiation. Journal of Biological Chemistry, 288(21), 14874-14885.
Scopus14 WoS13 Europe PMC112013 Thomas, D., Powell, J., Vergez, F., Segal, D., Nguyen, N., Baker, A., . . . Guthridge, M. (2013). Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 122(5), 738-748.
Scopus51 WoS51 Europe PMC372013 Lim, Y., Wright, J., Attema, J., Gregory, P., Bert, A., Smith, E., . . . Goodall, G. (2013). Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. Journal of Cell Science, 126(10), 2256-2266.
Scopus167 WoS154 Europe PMC1282013 Thomas, D., Powell, J., Green, B., Barry, E., Ma, Y., Woodcock, J., . . . Guthridge, M. (2013). Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biology, 11(3), 1-14.
Scopus19 WoS16 Europe PMC172013 Huang, M., Thomas, D., Li, M. X., Feng, W., Chan, S. M., Majeti, R., & Mitchell, B. S. (2013). Role of cysteine 288 in nucleophosmin cytoplasmic mutations: Sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia, 27(10), 1970-1980.
Scopus26 Europe PMC252012 Hercus, T., Broughton, S., Ekert, P., Ramshaw, H., Perugini, M., Grimbaldeston, M., . . . Lopez, A. (2012). The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors, 30(2), 63-75.
Scopus58 WoS55 Europe PMC432010 Lopez, A., Hercus, T., Ekert, P., Littler, D., Guthridge, M., Thomas, D., . . . Parker, M. (2010). Molecular basis of cytokine receptor activation. IUBMB Life, 62(7), 509-518.
Scopus59 WoS54 Europe PMC382010 Roberts, K. G., Smith, A. M., McDougall, F., Carpenter, H., Horan, M., Neviani, P., . . . Verrills, N. M. (2010). Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT<sup>+</sup> cancers. Cancer Research, 70(13), 5438-5447.
Scopus116 WoS112 Europe PMC772009 Jin, L., Lee, E., Ramshaw, H., Busfield, S., Peoppl, A., Wilkinson, L., . . . Lock, R. (2009). Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 5(1), 31-42.
Scopus442 WoS395 Europe PMC3332009 Powell, J., Thomas, D., Barry, E., Kok, C., McClure, B., Tsykin, A., . . . Guthridge, M. (2009). Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood, 114(23), 4859-4870.
Scopus52 WoS49 Europe PMC412009 Hercus, T., Thomas, D., Guthridge, M., Ekert, P., King-Scott, J., Parker, M., & Lopez, A. (2009). The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood, 114(7), 1289-1298.
Scopus251 WoS235 Europe PMC1742008 Lee, S., Ho, S., Thomas, D., Giri, P., Lee, H., Sia, H., . . . Sullivan, T. (2008). A partial nucleated differential cell count of the bone marrow aspirate that is independent of peripheral blood dilution. International Journal of Laboratory Hematology (Print Edition), 30(6), 473-479.
Scopus2 WoS1 Europe PMC22006 Mitchell, E., Thomas, D., & Burnet, R. (2006). Testosterone improves motor function in Parkinson's disease. Journal of Clinical Neuroscience, 13(1), 133-136.
Scopus45 Europe PMC262006 Guthridge, M., Powell, J., Barry, E., Stomski, F., Mc Clure, B., Ramshaw, H., . . . Lopez, A. (2006). Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO Journal, 25(3), 479-489.
Scopus68 WoS65 Europe PMC532004 Thomas, D., Vadas, M., & Lopez, A. (2004). Regulation of haematopoiesis by growth factors - emerging insights and therapies. Expert Opinion on Biological Therapy, 4(6), 869-879.
Scopus17 WoS16 Europe PMC141999 Stomski, F., Dottore, M., Winnall, W., Guthridge, M., Woodcock, J., Bagley, C., . . . Lopez, A. (1999). Identification of a 14-3-3 binding sequence in the common B chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 receptors that is serine-phosphorylated by GM-CSF. Blood, 94(6), 1933-1942.
Scopus45 WoS38 Europe PMC251998 Guthridge, M. A., Stomski, F. C., Thomas, D., Woodcock, J. M., Bagley, C. J., Berndt, M. C., & Lopez, A. F. (1998). Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells, 16(5), 301-313.
Scopus157 WoS144 Europe PMC100 -
Books
Year Citation 2005 Thomas, D., Guthridge, M., Woodcock, J., & Lopez, A. (2005). Protein Signaling in Development and Growth Factor Responses (Vol. 67). G. P. Schatten (Ed.), ELSEVIER ACADEMIC PRESS INC.
Scopus36 WoS34 Europe PMC25 -
Book Chapters
-
Patents
Year Citation 2017 Sinha, S., Ravindra, M., Dill, D. L., & Thomas, D. (2017). WO/2017/083716, Determination of Synthetic Lethal Partners of Cancer-Specific Alterations and Methods of Use Thereof. United States.
|
Date |
Project/No. |
Investigators |
Funding Body |
Amount |
|
2023-2025 |
Bioengineering a Superior Humanized Haematopoietic Niche Derived from Mesenchymal Stem Cells for Pre-Clinical Avatar Cancer Trials. MRF2024427 |
THOMAS D, Reinisch A, Thompson-Peach C, Powell J, Branford S, Arthur A, Pitson S, Hughes T, Ross D, Edney L. |
MRFF Stem Cell Therapies |
$854,594 |
|
2023 |
Anti-mutant CALR Antibody Preparation for Clinical Manufacture for Patients with Myelofibrosis. |
THOMAS D |
Therapeutic Innovation Australia Pipeline Accelerator |
$100,000 |
|
2022-2025 |
Identifying synthetic lethal and microenvironmental targets to improve outcome of therapy-related myeloid neoplasms. 2013617. |
Hiwase D, Hahn C, THOMAS D, Gronthos S, Godley L. |
Cancer Australia Priority-driven Collaborative Cancer Research Scheme. |
$563,770 |
|
2022-2025 |
Identification and Molecular Analysis of Pre-Myelofibrotic Stem Cells. FND000208. |
THOMAS D, Majeti R, Lopez A. |
Leukemia & Lymphoma Society |
US $600,000 |
|
2021-2026 |
Shining Light into the “unknown” on Indigenous and non-Indigenous Australians with Cancer of unknown Primary. MRF2007652 |
Karapetis C, Brown A, Kichendasse G, Pratt G, Scott H, Vajdic C, Waddell N, Corsini N, THOMAS D, Brown A. |
MRFF Improving Diagnosis in Cancers with Low Survival Rates. |
$2,401,509 |
|
2021-2024 |
ABOLISH Neuroblastoma: Defining the Aetiology and underlying BiOLogy of neuroblastoma to Innovate and SHape new options for prevention, diagnosis and treatment. MRF2007404. |
Khew-Goodall Y, Goodall G, Kirby M, Schwarz Q, Polo J, Wolvetang E, Pillman K, Jessop S, THOMAS D. |
MRFF Childhood Cancer Research |
$1,420,132 |
|
2021-2024 |
Engineered human stem cells for mutation-specific eradication of myelofibrosis. MRF2008972 |
THOMAS D, Reinisch A, Ross D, Babon J, Tvorogov D, Nair P, Morris R |
MRFF Stem Cell Therapies |
$853,275. |
|
2020-2024 |
Targeting Macromolecule Biosynthesis in Cancer by in vivo Flux Measurement of Primary Cells for Rational Drug Development. IF1320. |
THOMAS D |
Beat Cancer Project Infrastructure Grant |
$153,120 |
|
2020-2023 |
Personalized Metabolic Targeting of Epigenetic AML Mutations Through the Alpha-Ketoglutarate Pathway. ID 6619-21. |
Majeti R, THOMAS D. |
The Leukemia and Lymphoma Society Translational Research Program |
US$649,998. |
|
2020-2023 |
Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort. APP1201012. |
Hughes T, Hiwase D, Ross D, THOMAS D, Yeung D, Lane S, Yong A, Lopez A, Hercus T, Reynolds J. |
MRFF Rare Cancers Rare Diseases Unmet Need |
$1,619,122 |
|
2020-2022 |
Mutation-Centric Therapy for JAK2 vs CALR Mutated Myelofibrosis. APP1182564. |
Lopez A, Tvorogov D, THOMAS D |
NHMRC Ideas |
$661,237 |
|
2020-2022 |
Employing humanised xenotransplantation models of acute myeloid leukaemia to predict patient outcome and direct therapy. APP1184485. |
Pitson S, Powell J, THOMAS D. |
NHMRC Ideas |
$795,650 |
|
2020-2021 |
Pre-clinical Efficacy of ACC1 as a novel target for IDH1 Mutated Cancer. C-PJ-173-Exper-2019. |
THOMAS D. |
The Hospital Research Foundation Project Gran |
$69,000 |
|
2018-2019 |
Potent and Selective ACC1 inhibitor for Cancer with IDH1 Mutations |
THOMAS D, Majeti R. |
Stanford University |
US $75,000 |
|
2017-2022 |
Discovery of Synthetic Lethal Targets for Recurrent Epigenetic Mutations in Acute Myeloid Leukemia. APP ID 88686. |
THOMAS D. |
National Cancer Institute |
US $1,040,000 |
|
2014-2015 |
Data-Mining for Synthetic Lethal Targets in Acute Myeloid Leukemia. |
Majeti R, Dill D. L. |
National Institutes of Health |
US $500,000 |
|
2014-2015 |
SA PATH Equipment Grant. GNT9000253. |
Lopez A, Hughes T, Revesz T, THOMAS D. |
NHMRC |
$9,634 |
|
2012-2017 |
Targetting Quiescence Signalling Pathways in AML Stem Cells. APP1037514. |
THOMAS, D. |
NHMRC – Early Career Fellowship |
$274,434 |
Dr Thomas enjoys teaching and supervising 3rd year science students, Masters and PhD students in formal and informal sessions including regular Cancer Metabolism and Epigenetics journal club meetings at Level 4 SAHMRI Boardroom 2.30pm on Mondays
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2023 Principal Supervisor Discovery of novel metabolic targets against lDH1-mutant intrahepatic cholangiocarcinoma Doctor of Philosophy Doctorate Full Time Mrs Tasnova Tasnim Nova 2023 Principal Supervisor Novel Target Discovery for TP53 Mutated clonal Haematopoiesis Doctor of Philosophy Doctorate Full Time Mr Hossein Anani 2023 Co-Supervisor Fecal microbiota transplantation as an adjunctive supportive care therapy for haematopoietic stem cell transplantation recipients. Doctor of Philosophy Doctorate Full Time Miss Anna Li 2023 Principal Supervisor How Cancer Associated Fibroblasts Modify Stromal Landscape to Advance Malignant Progression of Breast Cancer Doctor of Philosophy Doctorate Full Time Mr Michael Antoniou 2023 Principal Supervisor The biological function of tryptophan metabolism in triple-negative breast cancer and cancer stem cells population Doctor of Philosophy Doctorate Full Time Mr Jamshid Motalebzadeh 2023 Principal Supervisor Peroxisome Biology in IDH1 Mutated Cancer Cells and Its potential for Target Therapy Doctor of Philosophy Doctorate Full Time Ms Mahta Moraghebi 2023 Co-Supervisor Synthetic lethality-based identification of metabolic targets for prostate cancer treatment Doctor of Philosophy Doctorate Full Time Mr Mohammad Asaad Ibrahim Ismail 2023 Principal Supervisor Modelling mutations in juvenile myelomonocytic leukaemia and chronic myelomonocytic leukaemia Doctor of Philosophy Doctorate Part Time Ms Kelly Lim 2022 Principal Supervisor A humanized monocyte model of TET2 mutated clonal hematopoiesis for noel target discovery Doctor of Philosophy Doctorate Full Time Miss Maha Kamel -
Other Supervision Activities
Date Role Research Topic Location Program Supervision Type Student Load Student Name 2021 - 2022 Principal Supervisor Discovering Novel Approaches in the Treatment of CALR mutant Myelofibosis University of Adelaide - Master - Suraiya Onnesha 2021 - 2021 Principal Supervisor A human cell model of juvenile myelomonocytic leukemia with a PTPN11 mutation University of Adelaide - Honours - Kzandrea Magday 2018 - 2018 Principal Supervisor Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethality vulnerability Stanford University - Other - Satinder Kaur -
Mentoring
Date Topic Location Name 2019 - 2023 Clonal architecture predicts clinical outcome and drug sensitivity Stanford University Brooks Bernard
-
Committee Memberships
Date Role Committee Institution Country 2022 - ongoing Member Acute Leukaemia and Myelodysplasia Working Committee Australasian Leukaemia and Lymphoma Group Australia 2022 - ongoing Member Braggs Comprehensive Cancer Centre Adelaide Health Innovation Partnership Australia -
Review, Assessment, Editorial and Advice
Date Title Type Institution Country 2019 - ongoing Associate Reviewer Peer Review Blood United States 2019 - ongoing Editor Peer Review PLOS ONE United States
Connect With Me
External Profiles
